Your browser doesn't support javascript.
loading
Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection.
Roozbehani, Mona; Falak, Reza; Mohammadi, Mohsen; Hemphill, Andrew; Razmjou, Elham; Meamar, Ahmad Reza; Masoori, Leila; Khoshmirsafa, Majid; Moradi, Maryam; Gharavi, Mohammad Javad.
Afiliación
  • Roozbehani M; Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Falak R; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Mohammadi M; Persian Gulf Marine Biotechnology Research Center, Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
  • Hemphill A; Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Razmjou E; Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Meamar AR; Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Masoori L; Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Khoshmirsafa M; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Moradi M; Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Gharavi MJ; Department of Parasitology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: gharavi.mj@iums.ac.ir.
Vaccine ; 36(41): 6124-6132, 2018 10 01.
Article en En | MEDLINE | ID: mdl-30181047
No effective human vaccine against Toxoplasma gondii (T. gondii) has yet been developed; however, a protective vaccine using immunogenic peptides in a safe delivery vehicle system offers promise. Here, we employed bioinformatics to design a multimeric recombinant T. gondii vaccine using predicted T and B cell epitopes of SAG1, AMA1, ROP2, and GRA4 proteins based on their binding capabilities to common major histocompatibility complex (MHC) molecules. Furthermore, we encapsulated the expressed protein in poly lactic-co-glycolic acid (PLGA) nanoparticles as a delivery vehicle and also used alum as an adjuvant to determine the vaccine potency of this multimeric antigen. BALB/c mice were vaccinated and then challenged with T. gondii RH strain, and the survival rate and cytokine profiles were studied. Mice vaccinated with the multi-epitope-based vaccine, both with and without PLGA, had greater Th1 immune responses, survival rates, specific antibody titers, and IFN-γ and IL-2 levels than controls, while the alum-adsorbed vaccine stimulated a Th2-type humoral immune response.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Toxoplasma / Vacunas Antiprotozoos / Nanopartículas / Copolímero de Ácido Poliláctico-Ácido Poliglicólico / Antígenos de Protozoos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Toxoplasma / Vacunas Antiprotozoos / Nanopartículas / Copolímero de Ácido Poliláctico-Ácido Poliglicólico / Antígenos de Protozoos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article País de afiliación: Irán